Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,959 Shares of Stock

Key Points

• Insider sale: Krishnan Viswanadhan sold 2,959 shares on March 5 at an average price of $27.80 for $82,260.20, reducing his stake by 36.53% to 5,141 shares.
• Market and analyst outlook: AGIO traded up 3.9% to $28.53 (market cap $1.67B) and several brokers have raised targets—Truist to $38, Leerink to $40 and Citi to $46—leaving an average price target of $40.67 and a consensus of six Buys, four Holds and one Sell (average rating: Hold).

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Krishnan Viswanadhan sold 2,959 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $27.80, for a total transaction of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares of the company's stock, valued at approximately $142,919.80. This trade represents a 36.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agios Pharmaceuticals Stock Up 3.9%

NASDAQ AGIO traded up $1.06 during midday trading on Monday, hitting $28.53. The company had a trading volume of 779,690 shares, compared to its average volume of 914,252. The firm has a fifty day simple moving average of $28.05 and a two-hundred day simple moving average of $33.22. Agios Pharmaceuticals, Inc. has a fifty-two week low of $22.24 and a fifty-two week high of $46.00. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -4.01 and a beta of 0.89.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AGIO. Truist Financial boosted their price target on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a "buy" rating in a research note on Wednesday, December 24th. Leerink Partners lifted their price objective on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an "outperform" rating in a report on Friday, December 26th. Wall Street Zen upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, February 14th. Citigroup upped their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Bank of America raised their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $40.67.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in AGIO. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at $183,000. Seven Fleet Capital Management LP acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $864,000. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth about $25,000. Invesco Ltd. lifted its holdings in Agios Pharmaceuticals by 12.3% during the 4th quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company's stock valued at $3,881,000 after purchasing an additional 15,604 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Agios Pharmaceuticals during the 4th quarter valued at about $1,253,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.